title: Treatment of POEMS syndrome with bevacizumab.
abstract: We report a case of POEMS syndrome which relapsed six years after autologous peripheral blood stem cell transplantation. According to encouraging data published recently, we treated the patient with cyclophosphamide, dexamethasone and the VEGF-antibody bevacizumab. After an initial improvement, the subsequent course was complicated by severe adverse events leading to multiorgan failure and death. This dramatic decline highlights the need for further investigation before using bevacizumab in patients with POEMS syndrome.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Samaras
authors.forename: Stefan
authors.initials: S
authors.lastname: Bauer
authors.forename: Frank
authors.initials: F
authors.lastname: Stenner-Liewen
authors.forename: Rudolf
authors.initials: R
authors.lastname: Steiner
authors.forename: Martin
authors.initials: M
authors.lastname: Zweifel
authors.forename: Christoph
authors.initials: C
authors.lastname: Renner
authors.forename: Alexander
authors.initials: A
authors.lastname: Knuth
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D016878:POEMS Syndrome / Q000097:blood / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab